Coya Therapeutics: Phase 2 LD IL-2 in Alzheimer's meets endpoints, shows cognitive stabilization

Coya Therapeutics, Inc.

Study met primary safety endpoint and secondary endpoint for Treg expansion with no off-target effects.
LD IL-2 q4wks showed cognitive stabilization (ADAS-Cog14 4.93-point improvement vs placebo, p=0.061).
Significant improvement in CSF Aß42 (p=0.045) and trend toward stabilizing CSF NfL (p=0.060) with q4wks.
Company likely advancing LD IL-2 q4wks; supports COYA 302 combination in ALS and FTD.
No serious adverse events or deaths; common AEs were mild injection-site erythema and eosinophil increases.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.